CYP2C19 phenotype-sensitive
- Clinical exposure depends strongly on CYP2C19 phenotype
- Genotype can shift efficacy and toxicity
- Strong inhibitors can mimic poor metabolism
- Prodrugs may show the opposite efficacy pattern
- Poor/rapid metabolizers can differ markedly.
Interaction at a glance
- Clinical exposure depends strongly on CYP2C19 phenotype
Mechanism
- Strong inhibitors can mimic poor metabolism
- Poor/rapid metabolizers can differ markedly.
Magnitude / time course
- Clinical exposure depends strongly on CYP2C19 phenotype
Clinical consequence
- Genotype can shift efficacy and toxicity
- Prodrugs may show the opposite efficacy pattern
Self-check
- What is the main clinical risk of CYP2C19 phenotype-sensitive?
Genotype can shift efficacy and toxicity.
Drugs in this interaction (13)
All interaction examples · Open the interactive console ↗
